StreetInsider.com News Articles

Goldman Sachs Reiterates Buy Rating on Stoke Therapeutics (STOK) Post Investor Meeting

Thu, 10 Sep 2026 04:57:07 -0400

Goldman Sachs analyst Kevin Strang reiterated a Buy rating and $44.00 price target on Stoke Therapeutics (NASDAQ: STOK).

The analyst comments "We hosted an investor meeting with Stoke Therapeutics (STOK) management, including Ian Smith (CEO), Jason Hoitt (Chief Patient Ocer), and Dawn Kalmar (Chief of Corporate Aairs & Strategic Partnerships). The discussion focused on the ongoing Ph3 EMPEROR study for zorevunersen in Dravet syndrome (ex-NA rights held by BIIB, covered by Salveen Richter), where management reiterated condence in the expected 3Q27 readout given: i) the totality of zorevunersen's prole thus far, including 4-year open-label extension data (recently showcased at the European

Stoke, Biogen share 4-year data on zorevunersen for Dravet syndrome

Fri, 04 Sep 2026 06:00:46 -0400

Stoke Therapeutics (Nasdaq: STOK) and Biogen (Nasdaq: BIIB) presented clinical data on zorevunersen, an investigational treatment for Dravet syndrome, at the 16th European Epilepsy Congress in Athens, Greece, running September 5-9.

The data, drawn from Phase 1/2a open-label extension studies, cover more than five years of clinical experience in patients with Dravet syndrome. Four-year results showed reductions in seizures and improvements in cognition and behavior in patients receiving zorevunersen alongside standard anti-seizure medicines. Statistically significant improvements in cognition and behavior were recorded at one, two, three, and four years compared to baseline.

A new exploratory sub-analysis showed reductions in generalized tonic-clonic and

Stoke, Biogen share 4-year data on zorevunersen for Dravet syndrome

Fri, 04 Sep 2026 06:00:46 -0400

A new exploratory sub-analysis showed reductions in generalized tonic-clonic and

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t

Thu, 03 Sep 2026 19:30:00 -0400

–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines–

–New data showed substantial reductions in the most severe seizure types, the leading risk factor for sudden unexpected death in epilepsy (SUDEP)–

–Improvements in quality of life were demonstrated through 28 months of treatment–

–Zorevunersen generally well tolerated, with some patients treated for more than 5 years–

–Data from the global, pivotal Phase 3

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t

Thu, 03 Sep 2026 19:30:00 -0400

–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines–

–New data showed substantial reductions in the most severe seizure types, the leading risk factor for sudden unexpected death in epilepsy (SUDEP)–

–Improvements in quality of life were demonstrated through 28 months of treatment–

–Zorevunersen generally well tolerated, with some patients treated for more than 5 years–

–Data from the global, pivotal Phase 3

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t

Thu, 03 Sep 2026 19:30:00 -0400

–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines–

–New data showed substantial reductions in the most severe seizure types, the leading risk factor for sudden unexpected death in epilepsy (SUDEP)–

–Improvements in quality of life were demonstrated through 28 months of treatment–

–Zorevunersen generally well tolerated, with some patients treated for more than 5 years–

–Data from the global, pivotal Phase 3

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t

Thu, 03 Sep 2026 19:30:00 -0400

–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines–

–New data showed substantial reductions in the most severe seizure types, the leading risk factor for sudden unexpected death in epilepsy (SUDEP)–

–Improvements in quality of life were demonstrated through 28 months of treatment–

–Zorevunersen generally well tolerated, with some patients treated for more than 5 years–

–Data from the global, pivotal Phase 3

Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress

Tue, 01 Sep 2026 07:30:47 -0400

Stoke Therapeutics (NASDAQ: STOK) and Biogen (NASDAQ: BIIB) announced plans to present clinical data on zorevunersen, an investigational treatment for Dravet syndrome, at the 16th European Epilepsy Congress (EEC) in Athens, Greece, running September 5–9.
The presentations include the first medical meeting disclosure of 4-year results from ongoing Phase 1/2a open-label extension (OLE) studies. According to the companies, improvements in cognition and behavior were sustained through four years, alongside seizure reductions and a generally well-tolerated safety profile. New sub-analyses also examined effects on the most severe seizure types and patient quality of life.
Of the 81 patients enrolled in the Phase 1/2a

Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress

Tue, 01 Sep 2026 07:30:47 -0400

Stoke Therapeutics (NASDAQ: STOK) and Biogen (NASDAQ: BIIB) announced plans to present clinical data on zorevunersen, an investigational treatment for Dravet syndrome, at the 16th European Epilepsy Congress (EEC) in Athens, Greece, running September 5–9.
The presentations include the first medical meeting disclosure of 4-year results from ongoing Phase 1/2a open-label extension (OLE) studies. According to the companies, improvements in cognition and behavior were sustained through four years, alongside seizure reductions and a generally well-tolerated safety profile. New sub-analyses also examined effects on the most severe seizure types and patient quality of life.
Of the 81 patients enrolled in the Phase 1/2a

Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress

Tue, 01 Sep 2026 07:30:47 -0400

Stoke Therapeutics (NASDAQ: STOK) and Biogen (NASDAQ: BIIB) announced plans to present clinical data on zorevunersen, an investigational treatment for Dravet syndrome, at the 16th European Epilepsy Congress (EEC) in Athens, Greece, running September 5–9.
The presentations include the first medical meeting disclosure of 4-year results from ongoing Phase 1/2a open-label extension (OLE) studies. According to the companies, improvements in cognition and behavior were sustained through four years, alongside seizure reductions and a generally well-tolerated safety profile. New sub-analyses also examined effects on the most severe seizure types and patient quality of life.
Of the 81 patients enrolled in the Phase 1/2a

Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress

Tue, 01 Sep 2026 07:30:47 -0400

Stoke Therapeutics (NASDAQ: STOK) and Biogen (NASDAQ: BIIB) announced plans to present clinical data on zorevunersen, an investigational treatment for Dravet syndrome, at the 16th European Epilepsy Congress (EEC) in Athens, Greece, running September 5–9.
The presentations include the first medical meeting disclosure of 4-year results from ongoing Phase 1/2a open-label extension (OLE) studies. According to the companies, improvements in cognition and behavior were sustained through four years, alongside seizure reductions and a generally well-tolerated safety profile. New sub-analyses also examined effects on the most severe seizure types and patient quality of life.
Of the 81 patients enrolled in the Phase 1/2a

Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress

Tue, 01 Sep 2026 07:30:47 -0400

Stoke Therapeutics (NASDAQ: STOK) and Biogen (NASDAQ: BIIB) announced plans to present clinical data on zorevunersen, an investigational treatment for Dravet syndrome, at the 16th European Epilepsy Congress (EEC) in Athens, Greece, running September 5–9.
The presentations include the first medical meeting disclosure of 4-year results from ongoing Phase 1/2a open-label extension (OLE) studies. According to the companies, improvements in cognition and behavior were sustained through four years, alongside seizure reductions and a generally well-tolerated safety profile. New sub-analyses also examined effects on the most severe seizure types and patient quality of life.
Of the 81 patients enrolled in the Phase 1/2a

Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress

Tue, 01 Sep 2026 07:30:47 -0400

Stoke Therapeutics (NASDAQ: STOK) and Biogen (NASDAQ: BIIB) announced plans to present clinical data on zorevunersen, an investigational treatment for Dravet syndrome, at the 16th European Epilepsy Congress (EEC) in Athens, Greece, running September 5–9.
The presentations include the first medical meeting disclosure of 4-year results from ongoing Phase 1/2a open-label extension (OLE) studies. According to the companies, improvements in cognition and behavior were sustained through four years, alongside seizure reductions and a generally well-tolerated safety profile. New sub-analyses also examined effects on the most severe seizure types and patient quality of life.
Of the 81 patients enrolled in the Phase 1/2a

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Cong

Tue, 01 Sep 2026 07:30:00 -0400

–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen–

–Improvements in cognition and behavior sustained through 4 years, in addition to durable seizure reductions and a generally well-tolerated safety profile–

–New data from sub-analyses of patients treated with zorevunersen in the Phase 1/2a OLEs include effects on severe seizures and quality of life–

BEDFORD, Mass. and CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Cong

Tue, 01 Sep 2026 07:30:00 -0400

–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen–

–Improvements in cognition and behavior sustained through 4 years, in addition to durable seizure reductions and a generally well-tolerated safety profile–

–New data from sub-analyses of patients treated with zorevunersen in the Phase 1/2a OLEs include effects on severe seizures and quality of life–

BEDFORD, Mass. and CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Cong

Tue, 01 Sep 2026 07:30:00 -0400

–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen–

–Improvements in cognition and behavior sustained through 4 years, in addition to durable seizure reductions and a generally well-tolerated safety profile–

–New data from sub-analyses of patients treated with zorevunersen in the Phase 1/2a OLEs include effects on severe seizures and quality of life–

BEDFORD, Mass. and CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Cong

Tue, 01 Sep 2026 07:30:00 -0400

–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen–

–Improvements in cognition and behavior sustained through 4 years, in addition to durable seizure reductions and a generally well-tolerated safety profile–

–New data from sub-analyses of patients treated with zorevunersen in the Phase 1/2a OLEs include effects on severe seizures and quality of life–

BEDFORD, Mass. and CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with

JPMorgan Reinstates Stoke Therapeutics (STOK) at Overweight

Fri, 21 Aug 2026 03:28:08 -0400

JPMorgan analyst Jessica Fye reinstates coverage on Stoke Therapeutics (NASDAQ: STOK) with a Overweight rating and a price target of $40.00.

For an analyst ratings summary and ratings history on Stoke Therapeutics click here. For more ratings news on Stoke Therapeutics click here.

Shares of Stoke Therapeutics closed at $31.40 yesterday.

Form 4 Stoke Therapeutics, Inc. For: Aug 14 Filed by: Ticho Barry

Tue, 18 Aug 2026 20:30:00 -0400
si-local-file:///var/storage/secattach/20260818/26946011.html

Form 4 Stoke Therapeutics, Inc. For: Aug 14 Filed by: Ticho Barry

Tue, 18 Aug 2026 20:30:00 -0400
si-local-file:///var/storage/secattach/20260818/26946011.html

Form 4 Stoke Therapeutics, Inc. For: Aug 14 Filed by: Kaye Edward M. MD

Tue, 18 Aug 2026 20:29:00 -0400
si-local-file:///var/storage/secattach/20260818/26946010.html

Form 4 Stoke Therapeutics, Inc. For: Aug 14 Filed by: Kaye Edward M. MD

Tue, 18 Aug 2026 20:29:00 -0400
si-local-file:///var/storage/secattach/20260818/26946010.html

Form 4 Stoke Therapeutics, Inc. For: Aug 14 Filed by: Allan Jonathan

Tue, 18 Aug 2026 20:27:00 -0400
si-local-file:///var/storage/secattach/20260818/26946006.html

Form 4 Stoke Therapeutics, Inc. For: Aug 14 Filed by: Allan Jonathan

Tue, 18 Aug 2026 20:27:00 -0400
si-local-file:///var/storage/secattach/20260818/26946006.html

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Tue, 18 Aug 2026 16:01:00 -0400

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on August 17, 2026, it granted stock options to purchase an aggregate of 70,950 shares of common stock to seven new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options that were granted have an exercise